FDA’s Guidance for 503A Compounding of COVID-19
Following our previous posts on FDA’s guidance released this week, Dr. David Hussong discusses the terms stipulated by the temporary policy which allows 503A pharmacies to compound certain drugs for COVID-19 without patient-specific prescriptions.
Watch this episode of Eagle TV to hear more! Have a question for our experts? Visit our COVID-19 resource page and access our fact check form to get science-based answers from our team.
Subscribe to our YouTube Channel to get alerts when we post videos
Eagle is a U.S. Food and Drug Administration (FDA) and Drug Enforcement Agency (DEA) registered A2LA ISO 17025 accredited laboratory founded in 2003 that provides analytical chemistry and microbiological testing, consultation services, and other technical services for pharmacies, highly regulated industries, and research organizations to support their compliance needs.
Latest posts by Eagle Analytical (see all)
- Antimicrobial Effectiveness | USP 795 & 797 Revisions - July 18, 2023
- 2023 PDA/FDA Joint Regulatory Conference, 09/18 – 09/20 - July 11, 2023
- APC: Compounders on Capitol Hill, 09/19 – 09/20 - July 11, 2023
